Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid in Thalassemia and Sickle Cell Anemia
NCT00346242Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2004
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of zoledronic acid in thalassemia, sickle cell anemia (SCA), sponsored by Novartis. Started Mar 2004; status: completed.
02
Drugs
zoledronic acid
03
Conditions
thalassemiasickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT00346242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00346242.